Latest News

Date Title Topic
28 Sep 2013 ESMO @ ECC 2013: Phase III FIRE-3 Trial Data Show Most Patients with Wild-Type RAS Metastatic Colorectal Cancer Benefit from First-Line FOLFIRI Plus Cetuximab Treatment Personalised medicine - Gastrointestinal cancers - Anticancer agents & Biologic therapy
28 Sep 2013 ECC 2013 Press Release: Hyperfractionated Radiotherapy Improves Survival in Head and Neck Cancer Patients Head and neck cancers
28 Sep 2013 ESMO @ ECC 2013: Premenopausal High-Risk Breast Cancer Patients with Luminal A Tumours Benefit from Postmastectomy Radiation Breast cancer
28 Sep 2013 ECC 2013 Press Release: Advanced melanoma: Pooled analysis of long-term survival with ipilimumab Melanoma - Immuno-oncology
28 Sep 2013 ECC 2013 Press Release: Anti-Cancer Drug T-DM1 Benefits Women with Avanced Breast Cancer who have Failed Several Previous Treatments: Results from TH3RESA Trial Breast cancer - Anticancer agents & Biologic therapy
ESMO Members' Lounge & Booth
26 Sep 2013 European Medicines Agency Recommends a Variation to the Terms of the Marketing Authorisation for Everolimus Central nervous system malignancies - Anticancer agents & Biologic therapy
25 Sep 2013 Primary Breast Cancer During Pregnancy: Does it Affect Outcome? Breast cancer
25 Sep 2013 European Medicines Agency Recommends to Extend the Indications for Ipilimumab Melanoma - Anticancer agents & Biologic therapy
New ESMO Publications
24 Sep 2013 RAS Mutations Predict a Lack of Response in Patients with Metastatic Colorectal Cancer who Receive Panitumumab–FOLFOX4 Personalised medicine - Gastrointestinal cancers
23 Sep 2013 European Medicines Agency Recommends Granting a Marketing Authorisation for Radium-223 Chloride Genitourinary cancers - Anticancer agents & Biologic therapy
23 Sep 2013 European Medicines Agency Recommends Granting a Marketing Authorisation for Trastuzumab Emtansine Breast cancer - Anticancer agents & Biologic therapy
18 Sep 2013 Clinical Tool Accurately Classifies Benign and Malignant Nodules on Lung Scans of Smokers Cancer prevention